The application of new genomics and proteomics techniques to our model, with its gradual stepwise development of pathological lesions, could be useful in identifying sequences of alterations of potential relevance to human prostate cancer, and in particular, cancers featuring the loss of PTEN. This evidence concerns the gene PTEN and prostate carcinoma.